These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21742835)

  • 21. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?
    Günther OP; Ogilvie G; Naus M; Young E; Patrick DM; Dobson S; Duval B; Noël PA; Marra F; Miller D; Brunham RC; Pourbohloul B
    J Infect Dis; 2008 Jun; 197(12):1653-61. PubMed ID: 18513154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
    Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
    Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of human papillomavirus vaccination in developed countries.
    Brisson M; Van de Velde N; Boily MC
    Public Health Genomics; 2009; 12(5-6):343-51. PubMed ID: 19684446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?
    Drolet M; Boily MC; Van de Velde N; Franco EL; Brisson M
    PLoS One; 2013; 8(6):e67072. PubMed ID: 23840589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
    Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
    Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
    Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females.
    Weiss TW; Zimet GD; Rosenthal SL; Brenneman SK; Klein JD
    J Adolesc Health; 2010 Jul; 47(1):3-11. PubMed ID: 20547286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How to best measure the effectiveness of male human papillomavirus vaccine programmes?
    Garland SM; Molesworth EG; Machalek DA; Cornall AM; Tabrizi SN
    Clin Microbiol Infect; 2015 Sep; 21(9):834-41. PubMed ID: 26055415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
    Thomas TL
    Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis.
    Malagón T; Joumier V; Boily MC; Van de Velde N; Drolet M; Brisson M
    Vaccine; 2013 Mar; 31(13):1740-7. PubMed ID: 23384753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty.
    Van de Velde N; Brisson M; Boily MC
    Am J Epidemiol; 2007 Apr; 165(7):762-75. PubMed ID: 17276976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
    Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of human papillomavirus vaccination.
    Ault KA
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.